Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **wound biofilm matrix** refers to the complex extracellular matrix produced by microbial communities colonizing a wound surface. It is not a single molecule or protein but rather a heterogeneous mixture of biological polymers, primarily **extracellular polysaccharides, proteins, extracellular DNA (eDNA), and often lipids**[1][4][5][7]. This matrix provides **structural integrity and protection** for embedded microbes, enhances resistance to antibiotics and immune reactions, and impedes wound healing by promoting chronic inflammation and interfering with tissue repair[3][5]. The composition can vary by species, local environment, and stage of biofilm development, commonly involving bacterial factors such as staphylococcal surface proteins, exopolysaccharides, and released cytoplasmic proteins[1][2][4]. In clinical terms, the biofilm matrix is a physical and biological barrier rather than a traditional therapeutic target (like a receptor or enzyme), and strategies targeting it often focus on degrading the matrix (e.g., enzymatic dispersal) or increasing its susceptibility to antimicrobial agents[5][3]. Because it is not a single molecular entity, but a composite non-protein structure, the “wound biofilm matrix” is not considered a canonical drug target, and listing it as such is scientifically inaccurate. **Summary:** - The “Wound biofilm matrix” is a **structural, multi-molecular extracellular matrix** made by wound microbes, **not a discrete drug target** in the sense of a protein, receptor, or enzyme[1][5]. - Its molecular makeup and complexity underlie the treatment challenges and clinical significance in chronic wound infections. - Targeting the matrix typically involves physical or enzymatic disruption, not precise receptor-ligand pharmacology.
Disruption of matrix structure (enzymatic degradation of DNA/proteins); Inhibition of biofilm formation or promotion of biofilm dispersal
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Wound biofilm matrix.